Overview

Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

Assess and compare the efficacy and safety of Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg and Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablet 50/100 mg in adult patients with Grade I-II arterial hypertension in 12 weeks of therapy

Phase:

Phase 3

Details

Lead Sponsor:

R-Pharm

Collaborators:

Boryung Pharmaceutical Co., Ltd
Covance

Treatments:

Losartan